No Data
Hims & Hers, LifeMD Shares Soar 20+% Amid Novo Nordisk Deal for Weight-Loss Drugs
TD Cowen Downgrades Hims & Hers Health(HIMS.US) to Hold Rating, Raises Target Price to $30
Citi Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $25
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Cuts Target Price to $40
Express News | B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $26
Top Midday Stories: Amazon Says Listing Tariff Pricing Never Considered for Main Site; Novo Nordisk Partners With Hims on Wegovy